AOD-9604 vs Semaglutide
Updated 5 sources
Key differences
- 1Semaglutide 2.4 mg weekly cut body weight by 14.9% vs 2.4% on placebo over 68 weeks in STEP 1.
- 2AOD-9604's largest trial (502 randomized, oral 0.25 to 1 mg for 24 weeks) found no significant weight-loss difference from placebo, and obesity development ended in 2007.
- 3Semaglutide suppresses appetite; AOD-9604 showed no appetite, glucose or insulin effect in animals.
- 4Semaglutide is an approved drug. AOD-9604 is unapproved and has no lawful compounding route.
Side by side
Facts from each record, in the same words as their own pages.
| AOD-9604 | Semaglutide | |
|---|---|---|
| Category |
|
|
| Evidence |
|
|
| FDA status |
|
|
| WADA |
|
|
| Half-life |
|
|
| Routes |
|
|
| Reported doses |
|
|
| Most cited frequency |
|
|
| Vial sizes |
|
|
| Mixed vial keeps |
|
|
| Protocols on file |
|
|
Doses shown are what sources report, labelled by origin. Not medical advice.
Read each in full
Sources
5 sources, each checked by date. Record updated Oct 23, 2026. Numbers are restated in our own words and labelled by where they came from.
Clinical study2
- Wilding et al. 2021, Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJMNEJM · checked Oct 23, 2026
- FDA Evaluation of AOD-9604-Related Bulk Drug Substances (PCAC briefing, 11/5/2024)FDA · checked Oct 23, 2026
Regulatory3
- Ozempic Prescribing Information (rev. 01/2025)FDA · checked Oct 23, 2026
- Wegovy injection and tablets label (SPL v19, Jun 30 2026)DailyMed · checked Oct 23, 2026
- Final Summary Minutes, PCAC Meeting December 4, 2024FDA · checked Oct 23, 2026